Welcome to our dedicated page for NASDAQ news (Ticker: nasdaq), a resource for investors and traders seeking the latest updates and insights on NASDAQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NASDAQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NASDAQ's position in the market.
Freshpet (NASDAQ: FRPT) announced that its entire U.S. and Canadian product portfolio earned the Clean Label Project Purity Award on Feb 12, 2026. Freshpet is the first and only pet food brand with full-line certification, following recipe testing that began in early 2025.
The nonprofit certification tests for more than 100 environmental and industrial contaminants including heavy metals, bisphenols, phthalates, acrylamide, and pesticides. Clean Label Project data showed fresh/frozen dog foods had the lowest heavy metal levels versus dry foods and human-consumable benchmarks.
Mammoth Energy Services (NASDAQ: TUSK) will host a conference call on Friday, March 6, 2026 to discuss fourth-quarter and full-year results for the period ended December 31, 2025. The call begins at 11:00 a.m. ET (10:00 a.m. CT) and will be webcast live on the company website.
A press release with results will be issued prior to the call and posted in Investor Relations. A telephonic replay is available through March 13, 2026 and an archived webcast will be posted after the call. Questions may be submitted in advance via TUSK@vizaraadvisors.com.
About Mammoth: Mammoth provides rental, infrastructure and energy services across North America, including equipment rentals, fiber optic engineering, sand proppant, directional drilling and workforce accommodations.
Atossa Therapeutics (NASDAQ: ATOS) reaffirmed its market position for (Z)-endoxifen in Duchenne muscular dystrophy (DMD) after Congress reauthorized the Rare Pediatric Disease Priority Review Voucher (PRV) program for five years on Feb 5, 2026. The drug holds Rare Pediatric Disease (RPD) designation and would be eligible for a PRV if FDA approval is obtained. PRVs can accelerate future reviews or be sold/transferred; disclosed PRV sales in the last 18 months ranged from $150–$200 million. Atossa cites emerging preclinical data and plans to advance the program toward clinical development for boys with DMD.
Atossa Therapeutics (NASDAQ: ATOS) announced on January 21, 2026 that Founder and CEO Steven Quay, M.D., Ph.D. was named one of The Top 50 Healthcare Technology CEOs of 2025 by The Healthcare Technology Report. The recognition cites his leadership advancing Atossa's lead therapy, (Z)-endoxifen, across multiple Phase 2 trials and its optimization as a SERM/D with added PKCβ1 inhibition to provide consistent systemic exposure independent of CYP2D6 metabolism.
The company is also exploring (Z)-endoxifen for Duchenne Muscular Dystrophy and highlights a people-centered, innovation-driven culture under Dr. Quay.
Atossa Therapeutics (NASDAQ: ATOS) announced that the U.S. Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD) on January 16, 2026. This designation follows a previously received Rare Pediatric Disease designation and supports continued development of (Z)-endoxifen in this rare pediatric neuromuscular disorder. The company said it will continue engaging with the FDA as it advances development efforts and will provide updates as appropriate.
Atossa Therapeutics (Nasdaq: ATOS) announced on January 6, 2026 that the U.S. Food and Drug Administration issued a "Study May Proceed" letter for its investigational new drug application for (Z)-endoxifen in metastatic ER+/HER2- breast cancer.
The company presented this as a regulatory milestone to advance a clinical study testing (Z)-endoxifen's activity, including in tumors with resistance to other endocrine therapies and targeting the oncogenic signaling pathway PKCβ1. No clinical efficacy or safety results were reported in this announcement.
Atossa Therapeutics (Nasdaq: ATOS) presented four clinical updates at SABCS 2025 on (Z)-endoxifen, covering DCIS active surveillance, low-dose I-SPY2 pilot data, ESR1-mutant mechanistic results, and the Phase 2 EVANGELINE neoadjuvant trial.
Key facts: daily 10 mg (Z)-endoxifen was well tolerated with 95% of patients completing ≥75% therapy; MRI tumor volume median change was -72%; ctDNA clearance occurred in 70% of initially positive patients; EVANGELINE run-in showed 86% with Week 4 Ki-67 ≤10% supporting a 40 mg Phase 2 dose.
1-800-FLOWERS.COM (NASDAQ: FLWS) appointed Alexander Zelikovsky as Chief Information Officer effective Dec 8, 2025. Zelikovsky will report to CEO Adolfo Villagomez and lead enterprise IT applications, data architecture, data management, cybersecurity, business intelligence, and support for AI and digital commerce initiatives.
This hire is positioned to accelerate the company’s digital transformation and omnichannel growth across its portfolio of brands.
Virax Biolabs Group (Nasdaq: VRAX) closed a private placement raising $5.0 million gross proceeds by issuing 12,500,000 ordinary shares (or equivalents) and preferred investment options to buy up to 12,500,000 ordinary shares at a combined price of $0.3999 per pre-funded warrant plus preferred option.
The pre-funded warrants are exercisable immediately at $0.0001 (no expiry). Preferred investment options are exercisable at $0.40 per share for five years from the effective date of a required registration statement. H.C. Wainwright acted as placement agent.
Net proceeds are intended for general working capital and are expected to extend cash runway into H1 2028, beyond planned completion and regulatory submissions for ViraxImmune US PASC study (FDA) and UK PAIS study (MHRA). The company agreed to register the resale of issued securities and to reduce and extend earlier preferred option terms (exercise price from $2.934 to $0.40 and extended term).
Virax Biolabs Group (Nasdaq: VRAX) announced a private placement to raise gross proceeds of approximately $5.0 million through the sale of 12,500,000 ordinary shares (or equivalents) and associated preferred investment options at $0.40 per share. The preferred investment options are exercisable immediately for five years from the effective date of an Initial Registration Statement. Closing is expected on or about December 4, 2025, subject to customary conditions. H.C. Wainwright is the exclusive placement agent. The company said net proceeds will be used for working capital and general corporate purposes. Virax agreed to file and seek effectiveness of a resale registration statement for the issued securities within specified timing and to repricing/extend prior Series A and B preferred options to the same terms.